Levofloxacin Mesylate for Injection

This product is the levorotatory form of ofloxacin, and its antibacterial activity is about twice that of ofloxacin. Its main mechanism of action is to inhibit the activity of bacterial DNA gyrase (bacterial topoisomerase II) and hinder the replication of bacterial DNA to achieve antibacterial effect. This product has the characteristics of broad antibacterial spectrum and strong antibacterial effect. It has strong antibacterial activity against most Enterobacteriaceae, such as Escherichia coli, Klebsiella, Serratia, Proteus, Shigella, Salmonella, Citrobacter, Acinetobacter, and Gram-negative bacteria such as Pseudomonas aeruginosa, Haemophilus influenzae, and Neisseria gonorrhoeae. It also has good antibacterial effect on some methicillin-sensitive Staphylococci, Streptococcus pneumoniae, Streptococcus pyogenes, hemolytic Streptococci, and Legionella, Mycoplasma, and Chlamydia, but has poor effect on anaerobic bacteria and enterococci.

The main ingredients of this product are: Levofloxacin mesylate

This product is a yellow or yellow-green clear liquid.

This product is suitable for the following moderate and severe infections caused by sensitive bacteria: respiratory system infections: acute bronchitis, acute exacerbation of chronic bronchitis, diffuse bacterial bronchitis, bronchiectasis and infection, pneumonia, tonsillitis (peritonsillar abscess); urinary system infections: pyelonephritis, complicated urinary tract infection, etc.; reproductive system infections: acute prostatitis, acute epididymitis, uterine cavity infection, uterine adnexitis, pelvic inflammatory disease (metronidazole can be used in combination when anaerobic infection is suspected); skin and soft tissue infections: infectious impetigo, cellulitis, lymphangiitis (adenitis), subcutaneous abscess, perianal abscess, etc.; intestinal infections: bacillary dysentery, infectious enteritis, salmonella enteritis, typhoid and paratyphoid; various infections in patients with sepsis, neutropenia and immunodeficiency; other infections: mastitis, trauma, burns and postoperative wound infection, abdominal infection (metronidazole can be used in combination when necessary), cholecystitis, cholangitis, bone and joint infection and ENT infection, etc.

This product should be prepared before use. First dissolve it with 5-10ml of 5% glucose injection or 5% glucose sodium chloride injection, then add it to 100ml of 5% glucose injection or 5% glucose sodium chloride injection for intravenous drip. This preparation is specially for intravenous drip, and the drip time is at least 60 minutes for every 100ml. This preparation should not be mixed with other drugs in the same bottle for intravenous drip, or for intravenous drip in one intravenous infusion line. Recommended dose: 400mg per day for adults, divided into 2 intravenous drips. For patients with severe infections and those with poor sensitivity of pathogens to this product (such as Pseudomonas aeruginosa), the maximum daily dose can be increased to 600mg, divided into 2 intravenous drips. For patients with impaired renal function, the dosage is determined according to the creatinine clearance rate. Creatinine clearance 50-80ml/minNormal dose 20-49ml/minFirst dose 400mg, then 200mg every 24 hours10-19ml/minFirst dose 400mg, then 200mg every 48 hours

During medication, you may experience symptoms such as nausea, vomiting, abdominal discomfort, diarrhea, loss of appetite, abdominal pain, and bloating; neurological symptoms such as insomnia, dizziness, and headache; rash, itching, erythema, and redness and itching at the injection site, or phlebitis. Transient liver function abnormalities may also occur, such as increased blood transaminase and increased serum total bilirubin. The incidence of the above adverse reactions is between 0.1% and 5%. Occasionally, blood urea nitrogen rises, fatigue, fever, palpitations, and abnormal taste are seen, which are generally tolerated and disappear quickly after the end of the course of treatment.

It is contraindicated for patients who are allergic to quinolones, pregnant or lactating women, and patients under 18 years of age.

Precautions for children: Not for use in patients under 18 years of age. Precautions for pregnancy and lactation: Not for use in pregnant and lactating women. Precautions for the elderly: Based on renal function, refer to the detailed information in the Usage and Dosage to determine the dosage. Or follow the doctor's advice.

1. This product cannot be used in the same infusion tube with polyvalent metal ion solutions such as magnesium and calcium. Avoid using it simultaneously with theophylline. If it is necessary to use it simultaneously, the blood concentration of theophylline should be monitored and the dosage should be adjusted accordingly. 2. When used simultaneously with warfarin or its derivatives, the prothrombin time or other coagulation tests should be monitored. 3. When used simultaneously with non-steroidal anti-inflammatory drugs, convulsions may be induced. 4. When used simultaneously with oral hypoglycemic drugs, hypoglycemia may be caused. Therefore, attention should be paid to monitoring blood sugar concentration during medication. Once hypoglycemia occurs, this product should be discontinued immediately and appropriate treatment should be given.

Keep away from light and store in a sealed container.

100mg

36 months